167 related articles for article (PubMed ID: 33047659)
1. Clinical-Pathologic Analysis of Breast Cancer With PIK3CA Mutations in Chinese Women.
Lian J; Xu EW; Xi YF; Wang HW; Bu P; Wang JF; Wang LX
Technol Cancer Res Treat; 2020; 19():1533033820950832. PubMed ID: 33047659
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients.
Deng L; Zhu X; Sun Y; Wang J; Zhong X; Li J; Hu M; Zheng H
Cancer Res Treat; 2019 Jan; 51(1):128-140. PubMed ID: 29540052
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Maruyama N; Miyoshi Y; Taguchi T; Tamaki Y; Monden M; Noguchi S
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):408-14. PubMed ID: 17202311
[TBL] [Abstract][Full Text] [Related]
4. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
5. PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [
Magometschnigg H; Pinker K; Helbich T; Brandstetter A; Rudas M; Nakuz T; Baltzer P; Wadsak W; Hacker M; Weber M; Dubsky P; Filipits M
Mol Imaging Biol; 2019 Oct; 21(5):991-1002. PubMed ID: 30652258
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China.
Cheng J; Fu S; Wei C; Tania M; Khan MA; Imani S; Zhou B; Chen H; Xiao X; Wu J; Fu J
Cancer Biomark; 2017; 19(1):85-92. PubMed ID: 28269754
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.
Li G; Guo X; Chen M; Tang L; Jiang H; Day JX; Xie Y; Peng L; Xu X; Li J; Wang S; Xiao Z; Dai L; Wang J
PLoS One; 2018; 13(9):e0203495. PubMed ID: 30212483
[TBL] [Abstract][Full Text] [Related]
8. Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
Ahmad F; Badwe A; Verma G; Bhatia S; Das BR
Med Oncol; 2016 Jul; 33(7):74. PubMed ID: 27282497
[TBL] [Abstract][Full Text] [Related]
9. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
[TBL] [Abstract][Full Text] [Related]
10. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
11. PIK3CA mutations in breast cancer: A Tunisian series.
Ben Rekaya M; Sassi F; Saied E; Bel Haj Kacem L; Mansouri N; Zarrouk S; Azouz S; Rammeh S
PLoS One; 2023; 18(5):e0285413. PubMed ID: 37195967
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
Li H; Zhu R; Wang L; Zhu T; Li Q; Chen Q; Wang H; Zhu H
Exp Mol Pathol; 2010 Feb; 88(1):150-5. PubMed ID: 19818761
[TBL] [Abstract][Full Text] [Related]
13. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
[TBL] [Abstract][Full Text] [Related]
14. ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Iwase H
Cancer Biomark; 2018; 22(2):345-350. PubMed ID: 29689710
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological Characteristics of
Lee MH; Cho JH; Kwon SY; Jung SJ; Lee JH
Int J Med Sci; 2020; 17(8):1131-1135. PubMed ID: 32410843
[TBL] [Abstract][Full Text] [Related]
16. PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma.
Kim HS; Lee SE; Bae YS; Kim DJ; Lee CG; Hur J; Chung H; Park JC; Shin SK; Lee SK; Lee YC; Kim HR; Shim YM; Jewell SS; Kim H; Choi YL; Cho BC
Oncotarget; 2016 May; 7(21):30691-701. PubMed ID: 27095573
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA mutation associates with improved outcome in breast cancer.
Kalinsky K; Jacks LM; Heguy A; Patil S; Drobnjak M; Bhanot UK; Hedvat CV; Traina TA; Solit D; Gerald W; Moynahan ME
Clin Cancer Res; 2009 Aug; 15(16):5049-59. PubMed ID: 19671852
[TBL] [Abstract][Full Text] [Related]
18. Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
Papaxoinis G; Kotoula V; Alexopoulou Z; Kalogeras KT; Zagouri F; Timotheadou E; Gogas H; Pentheroudakis G; Christodoulou C; Koutras A; Bafaloukos D; Aravantinos G; Papakostas P; Charalambous E; Papadopoulou K; Varthalitis I; Efstratiou I; Zaramboukas T; Patsea H; Scopa CD; Skondra M; Kosmidis P; Pectasides D; Fountzilas G
PLoS One; 2015; 10(10):e0140293. PubMed ID: 26452060
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing.
Jia M; Liao N; Chen B; Zhang G; Wang Y; Li X; Cao L; Mok H; Ren C; Li K; Li C; Wen L; Lin J; Wei G; Balch CM
Breast Cancer; 2021 May; 28(3):644-652. PubMed ID: 33386585
[TBL] [Abstract][Full Text] [Related]
20. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]